Activation of 5-HT and NR2B contributes to visceral hypersensitivity in irritable bowel syndrome in rats

被引：5
作者：
Chen, Ming-Xian [1 ,2 ]
Chen, Yu [3 ]
Fu, Rui [1 ]
Liu, Sai-Yue [4 ]
Yang, Qin-Qin [3 ]
Shen, Tang-Biao [1 ]
机构：
[1] Tongde Hosp Zhejiang Prov, Dept Gastroenterol, 234 Gucui Rd, Hangzhou 310012, Zhejiang, Peoples R China
[2] Zhejiang Prov Acad Tradit Chinese Med, Inst Integrated Chinese & Western Med Spleen Stom, Hangzhou, Zhejiang, Peoples R China
[3] Zhejiang Prov Acad Tradit Chinese Med, Lab Anim Ctr, Hangzhou, Zhejiang, Peoples R China
[4] Zhejiang Prov Ctr Adverse Drug React Monitoring, Dept Adverse Drug React Monitoring, 39 Yile Rd, Hangzhou 310012, Zhejiang, Peoples R China
来源：
AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH | 2016年 / 8卷 / 12期
基金：
中国国家自然科学基金;
关键词：
Irritable bowel syndrome; visceral hypersensitivity; 5-HT; NR2B; 5-HT2AR; 5-HT7R; COLORECTAL DISTENSION; COLON IRRITATION; NMDA RECEPTOR; PREDOMINANT; ANTAGONIST; IMPACT; MODEL; PAIN;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The roles of 5-hydroxytryptamine (5-HT) and spinal N-methyl-D-aspartic acid receptor 2B (NR2B) in visceral hypersensitivity were investigated. A rat model with irritable bowel syndrome (IBS) was established by intracolonic injections of acetic acid onpost-natal days 8-21. Rats were randomly divided into five groups: normal intact (control) group, IBS model group, Ro25-6981-treated IBS rats (Ro25-6981, a NR2B antagonist) group, amitriptyline-treated IBS rats (amitriptyline, a 5-HT antagonist) and Ro25-6981 plus amitriptyline-treated IBS rats (Ro25-6981+amitriptyline) group. The expressions of 5-HT, NR2B, 5-HT2AR, 5-HT7R, SERT, TNF-alpha and IL-1 beta in colon, dorsal root ganglion (DRG) and hypothalamus, respectively, were measured by Immunohistochemical staining, Real-Time Reverse Transcription-PCR and Western blotting. Our results showed increased DRG and hypothalamus expression of 5-HT, NR2B, 5-HT2AR, 5-HT7R in IBS model group and decreased expression of those in Ro25-6981 and amitriptyline alone or both treatment groups. Moreover, SERT expression was decreased in colorectal, DRG and hypothalamus of ISB model rats, but increased by Ro25-6981 and amitriptyline alone or both treatments. Ro25-6981 and amitriptyline treatment also decreased colorectal expression of TNF-a and IL-1 beta induced by IBS model. In conclusion, activation of 5-HT and NR2B may play a crucial role in visceral hypersensitivity in irritable bowel syndrome in rats.
引用
收藏
页码：5580 / 5590
页数：11
相关论文
共 33 条
  • [1] A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development
    Al-Chaer, ED
    Kawasaki, M
    Pasricha, PJ
    [J]. GASTROENTEROLOGY, 2000, 119 (05) : 1276 - 1285
  • [2] Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome
    Atkinson, W
    Lockhart, S
    Whorwell, PJ
    Keevil, B
    Houghton, LA
    [J]. GASTROENTEROLOGY, 2006, 130 (01) : 34 - 43
  • [3] Mechanisms underlying visceral hypersensitivity in irritable bowel syndrome
    Barbara G.
    Cremon C.
    De Giorgio R.
    Dothel G.
    Zecchi L.
    Bellacosa L.
    Carini G.
    Stanghellini V.
    Corinaldesi R.
    [J]. Current Gastroenterology Reports, 2011, 13 (4) : 308 - 315
  • [4] Review article: the economic impact of the irritable bowel syndrome
    Canavan, C.
    West, J.
    Card, T.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 40 (09) : 1023 - 1034
  • [5] Underlying molecular and cellular mechanisms in childhood irritable bowel syndrome
    Bruno P. Chumpitazi
    Robert J. Shulman
    [J]. Molecular and Cellular Pediatrics, 3 (1)
  • [6] Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome
    Coates, MD
    Mahoney, CR
    Linden, DR
    Sampson, JE
    Chen, J
    Blaszyk, H
    Crowell, MD
    Sharkey, KA
    Gershon, MD
    Mawe, GM
    Moses, PL
    [J]. GASTROENTEROLOGY, 2004, 126 (07) : 1657 - 1664
  • [7] Brain and gut interactions in irritable bowel syndrome: New paradigms and new understandings
    Coss-Adame E.
    Rao S.S.C.
    [J]. Current Gastroenterology Reports, 2014, 16 (4)
  • [8] Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials
    Cremonini, F
    Delgado-Aros, S
    Camilleri, M
    [J]. NEUROGASTROENTEROLOGY AND MOTILITY, 2003, 15 (01) : 79 - 86
  • [9] Irritable bowel syndrome - New agents targeting serotonin receptor subtypes
    De Ponti, F
    Tonini, M
    [J]. DRUGS, 2001, 61 (03) : 317 - 332
  • [10] Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: Plasma cytokines as a potential biomarker?
    Dinan, TG
    Quigley, EMM
    Ahmed, SMM
    Scully, P
    O'Brien, S
    O'Mahony, L
    O'Mahony, S
    Shanahan, F
    Keeling, PWN
    [J]. GASTROENTEROLOGY, 2006, 130 (02) : 304 - 311
1234